
Opinion|Videos|February 14, 2025
Final Thoughts on Bispecifics in B-Cell Lymphomas From ASH 2024
Panelists share their final thoughts on bispecific therapies in B-cell lymphomas based on insights from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition 2024.
Advertisement
Episodes in this series

Video content above is prompted by the following:
Thanks to all of you for this rich and informative discussion. Before we conclude, I’d like to get final thoughts from each of you.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
Amgen Direct-to-Patient Program Aims to Expand Access to Evolocumab Amid US Drug Pricing Reforms
3
Cohere Health Findings on AI in Prior Authorization Conflict With AMA Data
4
Contributor: Why Public Health Keeps Failing—and How to Fix It
5